Scynexis Prepares For NDA Filing With Second Phase III Success In VVC

 
• By Joseph Haas

Novel antifungal ibrexafungerp, a first-in-class triterpenoid, demonstrates ability to clear vulvovaginal candidiasis infections in second pivotal study; firm also looks to demonstrate efficacy in recurrent infections.

Detailed view of a sprinter getting ready to start. Selective focus.
With two successful Phase III studies, Scynexis is ready to file novel antifungal for approval

More from Clinical Trials

More from R&D